- Home
- CNA vs MRNA Comparison
CNA vs MRNA Comparison
Compare CNA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNA | MRNA |
|---|---|---|
| Founded | 1853 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 11.5B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNA | MRNA |
|---|---|---|
| Price | $46.93 | $56.07 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $33.00 |
| AVG Volume (30 Days) | 479.0K | ★ 9.5M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 8.24% | N/A |
| EPS Growth | ★ 33.24 | 21.77 |
| EPS | ★ 4.69 | N/A |
| Revenue | $14,989,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | N/A | $8.28 |
| Revenue Next Year | N/A | $16.53 |
| P/E Ratio | $10.16 | ★ N/A |
| Revenue Growth | ★ 5.04 | 4.29 |
| 52 Week Low | $43.29 | $22.28 |
| 52 Week High | $51.34 | $59.55 |
Technical Indicators
Market Signals| Indicator | CNA | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 64.12 |
| Support Level | $45.69 | $23.74 |
| Resistance Level | $47.38 | $59.55 |
| Average True Range (ATR) | 0.99 | 3.68 |
| MACD | -0.22 | 0.18 |
| Stochastic Oscillator | 11.65 | 68.55 |
Price Performance
Historical ComparisonAbout CNA CNA Financial Corporation
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.